Clinical Trials in Garden Grove, California
39 recruiting
Showing 1–20 of 37 trials
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled143 locationsNCT06159673
Recruiting
Phase 2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
Depressive Disorder, Major
Janssen Research & Development, LLC124 enrolled43 locationsNCT06785012
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar I DisorderBipolar II Disorder
AbbVie195 enrolled22 locationsNCT06696755
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
DepressionBipolar I Disorder
AbbVie380 enrolled78 locationsNCT04777357
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics280 enrolled175 locationsNCT05304767
Recruiting
Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting
Phase 2Phase 3
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Colitis Ulcerative
Bristol-Myers Squibb120 enrolled90 locationsNCT05076175
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled177 locationsNCT06029439
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled74 locationsNCT06058013
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche600 enrolled344 locationsNCT06819878
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled196 locationsNCT06588855
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca990 enrolled297 locationsNCT06883305
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative ColitisUlcerative Colitis Chronic
Eli Lilly and Company140 enrolled207 locationsNCT06598943
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Phase 1
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
DepressionHealthyMajor Depressive Disorder
Sirtsei Pharmaceuticals, Inc.36 enrolled2 locationsNCT06570369
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled60 locationsNCT06894212
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240